An interventional study of Legflow® balloon and Standard PTA in Atherosclerosis, sponsored by Cardionovum GmbH. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-23.
Sponsored by Cardionovum GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Atherosclerosis with a site in Belgium — 5 open to participants now, 9 under way, 6 of them phase 3. Atherosclerosis · Belgium.
Among the 46 studies in Atherosclerosis with a site in Belgium, this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 17 with no phase, and was the 28th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →5 of the 46 studies in Atherosclerosis with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Argentina and 25 more countries
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
CSL Behring · Sites in Belgium, United States, Argentina and 32 more countries
Ages 18+
Université Catholique de Louvain · Sites in Belgium
Ages 18+
Université Catholique de Louvain · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 13 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 328 across the 39 interventional studies, 304 across the 7 observational. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 46 have an industry lead sponsor. The 10 most frequent:
Cardionovum GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Cardionovum GmbH has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Atherosclerosis with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
Add it to your calendar (.ics) → With an account.
Among the 46 studies in Atherosclerosis with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized multicentric study for endovascular treatment of patients with obstructive disease in the SFA (superficial femoral artery) and in the popliteal artery.
This interventional study will collect data about the treatment of de novo lesions or restenotic lesions. Restenotic lesions that are previously DCB (drug coated balloon) treated or in-stent restenosis are excluded in this study.
The primary objective of this randomized study is to compare the efficacy of the DCB (Legflow - Cardionovum) versus POBA for the treatment of de novo lesions or restenosis in the SFA and in the popliteal artery (segment P1 -P2) by assessing the binary restenosis rate with duplex ultrasonography at 12 months.
The secondary endpoints are the assessment of the immediate procedural outcome, distribution of Rutherford, mortality, target lesion revascularization (TLR), target extremity revascularization (TER), amputation and anklebrachial index (ABI).
For each patient enrolled, data will be collected up to 12 months after the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
Device: Legflow® balloon
Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
Device: Standard PTA
Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
Also known as: Paclitaxel eluting balloon
Percutaneous angioplasty performed with a standard balloon
Also known as: POBA
Efficacy measured by binary restenosis rate
Binary restenosis rate determined by duplex ultrasonography at 1, 6 and 12 months afte procedure. Binary restenosis is defined as a re-obstruction ≥50% of the target lesion (peak systolic velocity ratio \> 2.4).
Time frame: Until 12 months after procedure
Immediate procedural outcome of percutaneous balloon angioplasty
Investigator opinion of procedural and technical success of the percutaneous angioplasty. Opinion of investigator (yes/no) is recorded in the CRF for technical success and procedural success.
Time frame: From start of procedure surgery until completion of procedure surgery (Percutaneous balloon angioplasty)
Rutherford
Distribution of Rutherford stages during follow-up as compared to baseline.
Time frame: Baseline until 12 months after procedure
Mortality
30-day mortality, 6-months mortality and overall mortality at 12 months.
Time frame: Until 12 months after procedure
Repeated target lesion revascularization (TLR) rate
TLR is defined as a repeated procedure (endovascular or surgical) due to a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena) initially treated in surviving patients with preserved limb.
Time frame: Until 12 months after procedure
Repeated target extremity revascularization (TER) rate
TER is defined as a procedure (endovascular or surgical) due to a problem arising in the ipsilateral traject (iliac, femoropopliteal and below the knee arteries) remote from the lesion initially treated in surviving patients with preserved limb.
Time frame: Until 12 months after procedure
Minor and major amputation rate
Occurrence of minor (below the ankle) and major (above the ankle) amputations.
Time frame: Until 12 months after procedure
Ankle-Brachial Index (ABI)
Reporting of Ankle-Brachial Index compared to baseline
Time frame: Baseline until 12 months after procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2016 to primary completion in Oct 2019, 43 months.
Of 198 interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 43 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardionovum GmbH